HRP20140876T1 - Rifaksimin u prahu, postupak za dobivanje istog i pripravci sa kontroliranim oslobađanjem koji sadrže navedeni rifaksimin te koji su korisni za dobivanje dugotrajnog djelovanja - Google Patents
Rifaksimin u prahu, postupak za dobivanje istog i pripravci sa kontroliranim oslobađanjem koji sadrže navedeni rifaksimin te koji su korisni za dobivanje dugotrajnog djelovanja Download PDFInfo
- Publication number
- HRP20140876T1 HRP20140876T1 HRP20140876AT HRP20140876T HRP20140876T1 HR P20140876 T1 HRP20140876 T1 HR P20140876T1 HR P20140876A T HRP20140876A T HR P20140876AT HR P20140876 T HRP20140876 T HR P20140876T HR P20140876 T1 HRP20140876 T1 HR P20140876T1
- Authority
- HR
- Croatia
- Prior art keywords
- rifaximin
- pharmaceutical preparation
- powder
- agents
- preparation according
- Prior art date
Links
- 229960003040 rifaximin Drugs 0.000 title claims 17
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title claims 16
- 239000000203 mixture Substances 0.000 title claims 6
- 239000000843 powder Substances 0.000 title claims 6
- 238000013270 controlled release Methods 0.000 title claims 2
- 230000005923 long-lasting effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000003086 colorant Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 239000000796 flavoring agent Substances 0.000 claims 2
- 235000003599 food sweetener Nutrition 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 239000003765 sweetening agent Substances 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003006 anti-agglomeration agent Substances 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000005461 lubrication Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- -1 softeners Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 239000012749 thinning agent Substances 0.000 claims 1
- 239000002966 varnish Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (12)
1. Postupak za pripravu rifaksimina u prahu koji ima spektar rendgenske difrakcije koji odgovara amorfnom obliku, sa veličinom čestica između 40 i 120 mikrometara u postotcima od 90% ukupnog broja čestica kao što je određeno pomoću Beckman-Coulter LS 100 Q analizatora veličine čestica opremljenog s mikro-volumenskom ćelijom, te nasipnu gustoću između 0.1 i 0.5 g/ml kao što je određeno pomoću 10 ml volumetrijske tikvice, naznačen time da ima slijedeće korake:
a) otapanje kristalnog ili amorfnog rifaksimina, ili njihove smjese, u organskim otapalima ili njihovim smjesama;
b) raspršivanje navedene otopine u fluidizatoru kod tlaka koji je između 0.5 i 2.5 bara u struji toplog zraka;
c) sušenje krutog rifaksimina do postizanja konstantne težine kod temperature koja je između 20°C i 120 °C.
2. Rifaksimin u prahu koji je dobiven postupkom prema zahtjevu 1 naznačen time da ima spektar rendgenske difrakcije koji odgovara amorfnom obliku i koji ima veličinu čestica između 40 i 120 mikrometara u postotcima od 90% ukupnog broja čestica kao što je određeno pomoću Beckman-Coulter LS 100 Q par analizatora veličine čestica opremljenog s mikro-volumenskom ćelijom, te nasipnu gustoću između 0.1 i 0.50 g/ml kao što je određeno pomoću 10 ml volumetrijske tikvice.
3. Rifaksimin u prahu prema zahtjevu 2 naznačen time da ima specifičnu površinu od između 0.01 i 10 m2/g kao što je određeno postupkom tekućeg plina.
4. Rifaksimin prema zahtjevu 2, naznačen time da je navedeni rifaksimin topiv u količini od između 5% i 90% u odnosu na ukupan rifaksimin sadržan u 750 ml pufera vodene otopine fosfata kod pH 6.8 i kod temperature od 30°C ± 0.5°C, nakon 150 minuta miješanja s miješalicom uz brzinu miješanja od 250 okr/min .
5. Farmaceutski pripravak naznačen time da sadrži rifaksimin u prahu prema zahtjevu 4 u količini između 10 i 800 mg i farmaceutski prihvatljive pomoćne tvari.
6. Farmaceutski pripravak prema zahtjevu 5, naznačen time da sadrži amorfni oblik rifaksimina u prahu u količini od 200 i 400 mg.
7. Farmaceutski pripravak prema zahtjevu 5 ili 6 u obliku tableta naznačen time da sadrži jedno ili više sredstava za razgradnju, sredstava za razrjeđivanje, zaslađivača, omekšivača, anti-aglomeracijskih sredstava, sredstva protiv ljepljenja, sredstva za pospješivanje klizanja, sredstva za vezanje, te proizvoljno sredstva za bojanje, pufer, sredstva za okus i zaslađivače.
8. Farmaceutski pripravak prema zahtjevu 7 u obliku tableta naznačen time da ima slijedeći sastav:
- amorfni oblik rifaksimina: 30%-70% (t/t)
- sredstvo za razgradnju: 3%-8% (t/t)
- sredstvo za podmazivanje: 2%-5% (t/t)
- sredstvo za pospješivanje klizanja: 0.1-2.0% (t/t)
- sredstvo za razrjeđivanje: 5%-65% (t/t)
i proizvoljno sredstvo za aromatiziranje i bojilo.
9. Farmaceutski pripravak prema zahtjevu 8 u obliku tableta naznačen time da ima slijedeći sastav:
- Rifaksimin: 10-800.0 mg
- natrijev škrobni glikolat: 5.0-30.0 mg
- glicerol distearat: 4.0-400.0 mg
- koloidni bezvodni silicijev dioksid: 0.2-10.0 mg
- sredstvo za klizanje, talk: 0.2-10.0 mg
- mikrokristalnu celulozu: 10.0-500.0 mg
i proizvoljno je obložen s premazom filma koji sadržava sredstvo za postizanje neprozirnosti, plastifikator i bojilo.
10. Farmaceutski pripravak prema zahtjevu 7 ili 8 naznačen time da je proizvoljno obložen s premazom filma koji sadržava sredstvo za postizanje neprozirnosti, plastifikator i bojilo.
11. Postupak za pripravu farmaceutskog pripravka prema bilo kojem zahtjevu od 5 do 10, naznačen time da ima slijedeće korake:
a) suho granuliranje rifaksimina dobivenog postupkom sušenja raspršivanjem, proizvoljno pomiješanog s rifaksiminom u kristalnom obliku ili u smjesi sa drugim hidratom, solvatom ili amorfnim oblikom rifaksimina i/ili u prisutnosti farmaceutski prihvatljivih pomoćnih tvari;
b) podmazivanje dobivenog granulata;
c) tabletiranje granulata iz koraka b) sa farmaceutski prihvatljivim pomoćnim tvarima;
d) proizvoljno, pripravu laka za premazivanje i premazivanje jezgri.
12. Farmaceutski pripravak prema jednom zahtjevu od 5 do 10 naznačen time da je za uporabu kod liječenja bakterijskih infekcija crijeva s kontroliranim otpuštanjem aktivnog sastojka.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2010A000370A IT1398550B1 (it) | 2010-03-05 | 2010-03-05 | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| PCT/IB2011/050933 WO2011107970A2 (en) | 2010-03-05 | 2011-03-04 | Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140876T1 true HRP20140876T1 (hr) | 2014-10-24 |
Family
ID=42697389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140876AT HRP20140876T1 (hr) | 2010-03-05 | 2014-09-15 | Rifaksimin u prahu, postupak za dobivanje istog i pripravci sa kontroliranim oslobađanjem koji sadrže navedeni rifaksimin te koji su korisni za dobivanje dugotrajnog djelovanja |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8748447B2 (hr) |
| EP (1) | EP2542225B1 (hr) |
| JP (1) | JP5932669B2 (hr) |
| KR (1) | KR101663491B1 (hr) |
| CN (1) | CN102781432B (hr) |
| AU (1) | AU2011222432B2 (hr) |
| BR (1) | BR112012021681A8 (hr) |
| CA (1) | CA2787123C (hr) |
| CL (1) | CL2012002124A1 (hr) |
| CO (1) | CO6551760A2 (hr) |
| DK (1) | DK2542225T3 (hr) |
| EA (1) | EA022324B1 (hr) |
| ES (1) | ES2496771T3 (hr) |
| HK (1) | HK1174263A1 (hr) |
| HR (1) | HRP20140876T1 (hr) |
| IL (1) | IL220792A (hr) |
| IT (1) | IT1398550B1 (hr) |
| MX (1) | MX2012010233A (hr) |
| NZ (1) | NZ602230A (hr) |
| PL (1) | PL2542225T3 (hr) |
| PT (1) | PT2542225E (hr) |
| RS (1) | RS53609B1 (hr) |
| SG (1) | SG182523A1 (hr) |
| SI (1) | SI2542225T1 (hr) |
| TN (1) | TN2012000362A1 (hr) |
| UA (1) | UA107208C2 (hr) |
| WO (1) | WO2011107970A2 (hr) |
| ZA (1) | ZA201205537B (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1698630B1 (en) | 2005-03-03 | 2014-09-03 | ALFA WASSERMANN S.p.A. | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| EP2401282B2 (en) | 2009-12-28 | 2017-01-04 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| CA2800235C (en) * | 2010-03-10 | 2018-10-16 | Lupin Limited | Rifaximin ready-to-use suspension |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| US9849090B2 (en) | 2012-12-12 | 2017-12-26 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of rifaximin |
| WO2016019372A1 (en) * | 2014-08-01 | 2016-02-04 | Bioxcel Corporation | Methods for reformulating and repositioning pharmaceutical data and devices thereof |
| WO2016063289A2 (en) * | 2014-10-22 | 2016-04-28 | Strides Arcolab Limited | Pharmaceutical tablet compositions comprising rifaximin |
| CN107580493A (zh) * | 2015-05-08 | 2018-01-12 | 沃克哈特有限公司 | 包含抗细菌剂的稳定的药物组合物 |
| ES2738024T5 (es) | 2016-03-24 | 2022-10-24 | Sandoz Ag | Composición estable al almacenamiento que comprende rifaximina alfa |
| US10576065B2 (en) | 2016-03-24 | 2020-03-03 | Sandoz Ag | Pharmaceutical composition containing rifaximin alpha and delta |
| PL3518924T3 (pl) | 2016-09-30 | 2023-01-09 | Salix Pharmaceuticals, Inc. | Postacie stałej dyspersji ryfaksyminy |
| WO2020208140A1 (en) * | 2019-04-12 | 2020-10-15 | Sandoz Ag | Rifaximin-containing granules |
| WO2023067485A1 (en) * | 2021-10-19 | 2023-04-27 | Zydus Lifesciences Limited | Pharmaceutical combinations |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
| DE3113139A1 (de) | 1981-04-01 | 1982-10-21 | Smit Transformatoren B.V., 6500 Nijmegen | "trockentransformator oder drosselspule mit luftkuehlung" |
| IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
| US5356625A (en) | 1986-08-28 | 1994-10-18 | Enzacor Properties Limited | Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
| GB8816620D0 (en) | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
| JP3350861B2 (ja) | 1990-06-29 | 2002-11-25 | アベンテイス・バルク・ソチエタ・ペル・アチオニ | リファペンチンの純粋の結晶型 |
| IT1253711B (it) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
| IT1264494B1 (it) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| WO1998016111A1 (en) | 1996-10-16 | 1998-04-23 | Shaman Pharmaceuticals, Inc. | Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
| IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
| US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
| US20030157174A1 (en) | 2000-03-23 | 2003-08-21 | Takayuki Tsukuda | Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| US6906087B2 (en) | 2000-10-31 | 2005-06-14 | Ciba Specialty Chemicals Corpation | Crystalline forms of venlafaxine hydrochloride |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| US20080262024A1 (en) | 2003-11-07 | 2008-10-23 | Giuseppe Claudio Viscomi | Rifaximin compositions and method of use |
| US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
| US7923553B2 (en) | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
| ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
| US20050196418A1 (en) | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| EP1698630B1 (en) | 2005-03-03 | 2014-09-03 | ALFA WASSERMANN S.p.A. | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
| EP2069363B1 (en) * | 2006-09-22 | 2013-03-20 | Cipla Ltd. | Rifaximin in an amorphous form |
| ITMI20071241A1 (it) | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
| US8974825B2 (en) | 2007-07-06 | 2015-03-10 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
| WO2009008005A1 (en) | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
| EP2837378A1 (en) | 2007-07-06 | 2015-02-18 | Lupin Limited | Pharmaceutical compositions of rifaximin |
| US7709634B2 (en) * | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
| SG188931A1 (en) | 2008-02-25 | 2013-04-30 | Salix Pharmaceuticals Ltd | Forms of rifaximin and uses thereof |
| US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
| WO2010044093A1 (en) | 2008-10-16 | 2010-04-22 | Strides Arcolab Limited | Formulations containing rifaximin |
| AU2009326167A1 (en) | 2008-12-10 | 2010-06-17 | Cipla Limited | Rifaximin complexes |
| IT1397617B1 (it) | 2009-04-20 | 2013-01-18 | Alfa Wassermann Spa | Nuovi derivati della rifamicina |
| ES2762442T3 (es) | 2009-10-26 | 2020-05-25 | Borody Thomas J | Novedosa terapia de combinación entérica |
| EP2493456B1 (en) | 2009-10-27 | 2018-11-21 | Lupin Limited | Solid dispersion of rifaximin |
| WO2011061748A1 (en) | 2009-11-19 | 2011-05-26 | Strides Arcolab Limited | Rifaximin premix |
| RU2012126080A (ru) | 2009-11-23 | 2013-12-27 | Сипла Лимитед | Местная пенообразующая композиция |
| JP2013511570A (ja) | 2009-11-23 | 2013-04-04 | シプラ・リミテッド | 局所用泡沫組成物 |
| EP2401282B2 (en) | 2009-12-28 | 2017-01-04 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
| CN101773465B (zh) | 2010-01-19 | 2012-11-07 | 南京泛太化工医药研究所 | 以氨基酸为稳定剂的聚合物胶束载药系统 |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| CA2800235C (en) | 2010-03-10 | 2018-10-16 | Lupin Limited | Rifaximin ready-to-use suspension |
| CN103269587A (zh) | 2010-06-03 | 2013-08-28 | 萨利克斯药品有限公司 | 利福昔明的新形式及其用途 |
| US8883795B2 (en) | 2010-06-16 | 2014-11-11 | Apotex Pharmachem Inc. | Polymorphic forms of Rifaximin |
| CN103228662B (zh) | 2010-07-12 | 2016-08-10 | 萨利克斯药品有限公司 | 利福昔明的制剂及其用途 |
| US8759513B2 (en) | 2010-09-13 | 2014-06-24 | Sequent Scientific Limited | Polymorphic form of rifaximin and process for its preparation |
| US20130315988A1 (en) | 2010-09-13 | 2013-11-28 | Cipla Limited | Pharmaceutical Composition |
| IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
| WO2012076832A1 (en) | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
| PL2672970T3 (pl) | 2011-02-11 | 2018-11-30 | Salix Pharmaceuticals, Ltd. | Postacie rifaksyminy i sposoby ich wykorzystania |
| AU2012251385A1 (en) | 2011-05-02 | 2013-11-21 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
| ITMI20110890A1 (it) | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| US9359374B2 (en) | 2012-06-13 | 2016-06-07 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
| US9849090B2 (en) | 2012-12-12 | 2017-12-26 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of rifaximin |
| ITMI20131307A1 (it) | 2013-08-02 | 2015-02-02 | A M S A Anonima Materie Sint & Affini S P A | Processo per la preparazione di refaximina k |
-
2010
- 2010-03-05 IT ITMI2010A000370A patent/IT1398550B1/it active
-
2011
- 2011-03-04 AU AU2011222432A patent/AU2011222432B2/en active Active
- 2011-03-04 SG SG2012051975A patent/SG182523A1/en unknown
- 2011-03-04 BR BR112012021681A patent/BR112012021681A8/pt not_active Application Discontinuation
- 2011-03-04 SI SI201130298T patent/SI2542225T1/sl unknown
- 2011-03-04 WO PCT/IB2011/050933 patent/WO2011107970A2/en active Application Filing
- 2011-03-04 EA EA201290734A patent/EA022324B1/ru unknown
- 2011-03-04 NZ NZ602230A patent/NZ602230A/xx unknown
- 2011-03-04 JP JP2012555537A patent/JP5932669B2/ja not_active Expired - Fee Related
- 2011-03-04 PT PT117146639T patent/PT2542225E/pt unknown
- 2011-03-04 RS RS20140619A patent/RS53609B1/en unknown
- 2011-03-04 EP EP11714663.9A patent/EP2542225B1/en active Active
- 2011-03-04 CN CN201180012550.XA patent/CN102781432B/zh active Active
- 2011-03-04 US US13/582,676 patent/US8748447B2/en active Active
- 2011-03-04 DK DK11714663.9T patent/DK2542225T3/da active
- 2011-03-04 KR KR1020127022961A patent/KR101663491B1/ko active IP Right Grant
- 2011-03-04 MX MX2012010233A patent/MX2012010233A/es unknown
- 2011-03-04 PL PL11714663T patent/PL2542225T3/pl unknown
- 2011-03-04 ES ES11714663.9T patent/ES2496771T3/es active Active
- 2011-03-04 CA CA2787123A patent/CA2787123C/en active Active
- 2011-04-03 UA UAA201208484A patent/UA107208C2/uk unknown
-
2012
- 2012-07-05 IL IL220792A patent/IL220792A/en active IP Right Grant
- 2012-07-17 TN TNP2012000362A patent/TN2012000362A1/en unknown
- 2012-07-23 ZA ZA2012/05537A patent/ZA201205537B/en unknown
- 2012-07-30 CO CO12127400A patent/CO6551760A2/es not_active Application Discontinuation
- 2012-07-31 CL CL2012002124A patent/CL2012002124A1/es unknown
-
2013
- 2013-01-31 HK HK13101372.1A patent/HK1174263A1/xx unknown
-
2014
- 2014-04-24 US US14/261,337 patent/US9498442B2/en active Active
- 2014-09-15 HR HRP20140876AT patent/HRP20140876T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140876T1 (hr) | Rifaksimin u prahu, postupak za dobivanje istog i pripravci sa kontroliranim oslobađanjem koji sadrže navedeni rifaksimin te koji su korisni za dobivanje dugotrajnog djelovanja | |
| HRP20192064T1 (hr) | Formulacije apiksabana | |
| SA515360113B1 (ar) | تركيبة دوائية مغلفة تحتوي على ريجورافنيب | |
| FI2914248T4 (fi) | Farmaseuttisia koostumuksia cftr-välitteisten tautien hoitamiseksi | |
| HRP20200315T1 (hr) | Čvrsti oralni pripravci na bazi soli s-adenozilmetionina i postupak njihove priprave | |
| HRP20090198A9 (hr) | Upotreba poliola za dobivanje stabilnih oblika rifaksimina | |
| CN106349797B (zh) | 一种用于捕获甲醛的乙烯脲复合纳米材料及制备方法 | |
| HRP20151383T4 (hr) | Farmaceutski pripravci koji sadrže nilotinib ili njegovu sol | |
| CN102319263B (zh) | 一种含多种维生素和矿物质的薄膜包衣片及其制备工艺 | |
| RU2017134002A (ru) | Стабильные композиции тетрагидробиоптерина | |
| BR112012003592B1 (pt) | composição farmacêutica contendo derivado de quinolina | |
| SI2207526T1 (en) | A process for the manufacture of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, a pharmaceutical composition comprising the granules obtained according to such a process and its intermediates | |
| HRP20161340T1 (hr) | Formulacije darunavira | |
| PT1954251E (pt) | Composição de libertação prolongada da substância ativa, seu método de preparação e sua utilização | |
| HRP20200642T1 (hr) | Čvrsti obrazac za doziranje koji sadrži mikronizirani citizin | |
| ES2375265T3 (es) | Composiciones farmacéuticas de pramipexol. | |
| CN103142525B (zh) | 奥氮平胃溶型片剂及其制备方法 | |
| RU2010106616A (ru) | Составы таблеток против вич, содержащие дарунавир | |
| ES2497065T3 (es) | Procedimiento para la preparación de comprimidos que comprenden S-adenosilmetionina | |
| CN107595782A (zh) | 一种利奈唑胺干混悬剂及其制备方法 | |
| TW201909888A (zh) | 包衣組成物、包衣膜、包衣製劑及其製造方法 | |
| US20110287140A1 (en) | Process for preparing a free-flowing powder containing a deliquescent quaternary ammonium compound | |
| HRP20150410T1 (hr) | Novi pripravci za terapiju esencijalne trombocitemije | |
| HRP20192328T1 (hr) | Farmaceutski pripravci koji sadrže niske doze lijekova | |
| JP2021134168A (ja) | 固形製剤及びその製造方法 |